REVIEW

Recent advances in understanding and managing chordomas

[version 1; peer review: 2 approved]

Carl Youssef, Salah G. Aoun , Jessica R. Moreno, Carlos A. Bagley

Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas, Texas, 75390, USA

V1 First published: 22 Dec 2016, 5(F1000 Faculty Rev):2902
<https://doi.org/10.12688/f1000research.9499.1>

Latest published: 22 Dec 2016, 5(F1000 Faculty Rev):2902
<https://doi.org/10.12688/f1000research.9499.1>

Abstract

Chordomas are rare primary bone tumors arising from embryonic remnants of the notochord. They are slow-growing, locally aggressive, and destructive and typically involve the axial skeleton. Genetic studies have identified several mutations implicated in the pathogenesis of these tumors. Treatment poses a challenge given their insidious progression, degree of local invasion at presentation, and high recurrence rate. They tend to respond poorly to conventional chemotherapy and radiation. This makes radical resection the mainstay of their treatment. Recent advances in targeted chemotherapy and focused particle beam radiation, however, have improved the management and prognosis of these tumors.

Keywords

chordoma, chordomas, primary bone tumours, primary bone tumors, focused particle beam radiation, targeted chemotherapy

Open Peer Review

Approval Status

	1	2
version 1 22 Dec 2016		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Omer Faruk Bayrak**, Yeditepe University Medical School and Yeditepe University Hospital, Istanbul, Turkey
2. **Maurice Matter**, University Hospital of Lausanne (CHUV), Lausanne, Switzerland

Any comments on the article can be found at the end of the article.

Corresponding author: Carlos A. Bagley (carlos.bagley@gmail.com)

Competing interests: The authors declare that they have no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2016 Youssef C *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Youssef C, Aoun SG, Moreno JR and Bagley CA. **Recent advances in understanding and managing chordomas [version 1; peer review: 2 approved]** F1000Research 2016, 5(F1000 Faculty Rev):2902 <https://doi.org/10.12688/f1000research.9499.1>

First published: 22 Dec 2016, 5(F1000 Faculty Rev):2902 <https://doi.org/10.12688/f1000research.9499.1>

Introduction

Chordomas are primary bone tumors typically involving the axial skeleton. They are rare and account for only 1% to 4% of all primary malignant bone tumors; they have an incidence of 300 newly diagnosed cases every year^{1,2}. Presentation occurs at an older age compared with other tumors of the spine (59.9 ± 17 years)³. Males are more affected than females (59.5%), and Caucasians and Hispanics are four times more prone to the disease than African-Americans¹. Although these tumors were previously thought to arise more frequently in the sacrum, a recent US population-based database study showed that tumor distribution was relatively even between the skull base (32%), mobile spine (32.8%), and the sacrum (29.2%) and that the remainder (6%) were in various extra-axial locations¹. Median survival rate is approximately 7 years, and 5-, 10-, and 20-year survival rates are 68%, 40%, and 13%, respectively¹.

Clinical features

The clinical presentation of chordomas varies with tumor location, since these lesions are slow-growing and can be locally destructive. Cranial tumors frequently present initially with headaches and diplopia. Symptoms can evolve to include cranial nerve palsies, visual loss, seizures, extremity weakness or numbness, neck pain, nasal congestion, or dysphagia as adjacent structures are progressively infiltrated or compressed⁴. On the other hand, chordomas of the spine and sacrococcygeal region usually present with local pain or with signs of neural compression, such as radiculitis, bowel or urinary incontinence, or sexual dysfunction. In advanced cases of sacrococcygeal disease, the mass can be palpated during rectal or gynecologic examination^{5,6}.

In addition to classic clinical features, imaging plays an important role in establishing a correct diagnosis. Chordomas often appear on plain films as a destructive bone lesion with associated soft tissue calcification^{7,8}. In contrasted computed tomography (CT) scans, chordomas usually show as a contrast-enhancing, lytic, or mixed bony lesion. They often have a myxoid component that is seen as a well-demarcated soft tissue mass containing areas of hypodensity. Their overall density is comparable to that of muscle, and calcifications are usually present, particularly in the sacrococcygeal area^{9,10}. On magnetic resonance imaging (MRI), chordomas are hypointense or isointense on T1-weighted sequences and hyperintense on T2-weighted sequences. They tend to enhance heterogeneously with gadolinium, creating a lobulated “honeycomb” appearance¹¹. This is due to fluid, including gelatinous mucoid substance, old hemorrhage, or areas of necrosis within the tumor. Unlike osteosarcomas and chondrosarcomas of the spine, chordomas often involve the intervertebral disk as they invade adjacent vertebral segments, and they exhibit decreased or normal isotope uptake on scintigraphic studies^{5,12}.

Despite fairly recognizable features on imaging, a timely diagnosis is often difficult to make. This is due mainly to the insidious nature of these tumors, as they frequently present with lingering chronic headaches or back pain that does not prompt patients to seek medical attention immediately¹³. In addition, sacral lesions may go undetected on imaging, as CT and MRI scans often do not extend below the S2 level unless specifically ordered⁵.

Pathogenesis and genetics

Chordomas are believed to arise from embryonic remnants of the notochord. Histologically, both the notochord and chordomas consist of a nest of large, vacuolated, physaliphorous cells surrounded by an extracellular myxoid matrix^{14,15}. The anatomic distribution of chordomas along the axial skeleton also respects the longitudinal midline axis formed by the notochord during embryonic development.

More recently, a strong genetic link corroborating the relationship between chordomas and the notochord has been established. The “T” gene, located on chromosome 6q27, encodes the “Brachyury” protein and is an evolutionarily favored gene that plays a critical role in the development of the notochord and in defining the midline of bilaterian organisms¹⁶. Duplications in this gene have been found to confer major susceptibility in studies of familial chordomas, and its amplification has also been implicated in sporadic cases^{17–20}. Interestingly, silencing of the Brachyury gene in chordoma cells *in vitro* leads to complete growth arrest and senescence²¹. The Brachyury gene is also implicated in various human carcinomas and could be responsible for the epithelial-mesenchymal transition allowing tumors to metastasize^{22–25}. In addition, the uniquely high levels of expression of the Brachyury protein in chordomas have allowed scientists and labs to differentiate them from other tumors of the neuroaxis, such as chondrosarcomas, with relatively high sensitivity and specificity^{26–31}. The degree of Brachyury expression, however, has not shown a prognostic indication in chordomas³².

Recent molecular analyses have revealed additional genetic abnormalities involved in the pathogenesis of chordomas. Evidence of activation of the *PI3K/AKT/TSC1/TSC2/mTOR* signaling pathway was detected in chordoma cells³³. On the other hand, the Stat3 pathway was found to be constitutively active in these tumors, and its level of expression was closely correlated with disease severity and survival³⁴. Not surprisingly, aberrant epidermal growth factor receptor (*EGFR*) signaling has also been implicated in their pathogenesis³⁵. Furthermore, the activation of the *IGF1R* and loss of *MTAP*, an essential enzyme in the purine salvage pathway, were also detected³⁶. The analysis of existing chordoma cell lines has revealed additional genetic aberrations, including the loss of p16, *PTEN*, *CDKN2a/CDKN2b*, and *PDCD4*^{37,38}. Studies of skull base lesions have implicated losses on chromosome 1p and the *FHIT* gene and gains on 1q and 2p in their pathogenesis^{39,40}. These findings demonstrate non-random genetic alterations, in which losses are more frequent than gains, and pave the way to developing targeted treatments for these tumors⁴¹.

As in other neoplasms, epigenetic alterations play an important role in understanding the tumorigenesis process, but they also provide invaluable diagnostic, prognostic, and potentially therapeutic molecular tools. Duan *et al.* provided data on microRNA (miRNA) expression in chordomas and demonstrated several miRNAs that are differentially expressed in chordoma cell lines compared with controls⁴². The therapeutic potential of miRNAs is evident from multiple studies such as that by Zhang *et al.*, in which *EGFR*, *MET*, and *Bcl-xL* were identified as targets of two downregulated miRNAs that, when restored, were able to inhibit cell proliferation and

invasion and induce apoptosis in chordoma cells⁴³. Similarly, Osaka *et al.* demonstrated that microRNA-1 is downregulated in chordoma and that its restoration suppressed not only proliferation but also migratory and invasive activities and reduced expression of the oncoprotein Slug⁴⁴. Further evidence on the epigenetic component of chordoma pathogenesis comes from a study by Scheipl *et al.*, in which non-selective histone deacetylase inhibitors have been shown to significantly increase apoptosis of chordoma cells *in vitro*⁴⁵.

Treatment

The management of chordomas is complex and continually evolving. Despite being histologically classified as low-grade tumors, chordomas are locally invasive and highly recurrent, which makes their prognosis similar to that of more malignant lesions^{6,46}. The slow-growing nature of these tumors and their low cellular turnover rate also render them clinically resistant to traditional chemotherapy, and they have only limited *ex vivo* response to a few agents, such as doxorubicin, Yondelis, Zalypsis, and cisplatin^{37,47}. The use of traditional radiation therapy is also limited, as the tolerance of the spinal cord and brainstem to the doses required for clinical effectiveness is restricted^{48,49}. For all of these reasons, the mainstay of treatment of chordomas remains aggressive surgical resection with wide surgical margins^{47,50,51}. However, en bloc surgical resection can be challenging because of frequent proximity to or invasion of vital neural structures. As a result, intra-lesional excision or partial debulking in order to decompress vital structures is often the only available option, which may lead to tumor seeding or significant residual tumor or both³². In one study, the disease-free interval for patients undergoing radical resection for sacral chordoma was 2.27 years, compared with only 8 months for patients who underwent subtotal excision⁴⁷. In another study, patients who underwent surgical resection survived significantly longer than those who did not undergo resection, regardless of adjuvant therapy (151 versus 81 months)⁵³. Unfortunately, prognosis remains disappointing even with successful en bloc resection, and the disease-free interval is relatively short⁵⁰.

Advances in surgical techniques have allowed surgeons to approach chordomas with less invasive resections. For clival chordoma, multiple studies have demonstrated that the endoscopic endonasal approach provides an effective, yet less invasive and more direct, corridor to the clivus compared with the traditional open craniotomy and transoral techniques^{54–57}. On the other hand, surgical resection (posterior only or combined anterior-posterior approaches) of sacral chordoma has remained invasive given the typically large size of the tumor and the degree of local invasion at the time of diagnosis. However, advances in surgical resection and reconstruction techniques have allowed for more preservation of nerve roots and decreases in operative time and blood loss^{58–60}. In the case of chordomas of the mobile spine, newer techniques, such as complete spondylectomy, have been developed to widen the margin of resection and to decrease local recurrence^{61,62}.

The main role of radiation therapy in the management of chordomas has been as an adjuvant treatment to surgery. Residual disease after surgery rarely regresses and often leads to progression, regardless of the radiation dose delivered⁶³. However, recent

advances in particle beam therapy, such as proton beam and carbon ion beam, hold some promise. In a very recent study assessing proton therapy in combination with surgical resection for skull base chordomas, the reported 5- and 7-year local control rates were 75.8% and 70.9%, respectively⁶⁴. Another systematic review also concluded that proton therapy improves long-term local control and survival in patients with skull base chordoma⁶⁵. In tumors of the sacrum and spine, surgical resection coupled with proton therapy provided a 5-year overall survival and local control rate of 81% and 62%, respectively⁶⁶. Carbon ion beam appears to be comparable to proton therapy. In a study of skull base chordomas treated with surgical resection followed by carbon ion radiation, local control was reported to be as high as 80.6% and 70.0% at 3 and 5 years, respectively⁶⁷. In another study on the effectiveness of carbon ion therapy in patients with unresectable sacral chordomas, carbon ion therapy appeared to provide a promising alternative to surgery in slowing disease progression, offering a markedly high 89% 5-year local control rate⁶⁸. More recently, a study on the utility of particle beam therapy (carbon ion or protons) in patients with primary sacral chordoma also reported promising results: 3-year local control, overall survival, and progression-free survival of 94%, 83%, and 68%, respectively⁶⁹.

Despite the promising outcomes of particle beam radiation in the treatment of chordomas, its use is still limited; specialty centers are needed to house the machines because of their size, and treatment remains expensive⁷⁰. Furthermore, owing to the rarity of the disease and the difficulty in randomly assigning patients into groups other than the standard of care, there are currently no published data from randomized trials assessing these new tools⁷¹. Nonetheless, a randomized trial comparing proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma is under way⁷².

With the aforementioned challenges in the management of this complex disease, the quality of life of patients with chordoma is an integral aspect of patient management and counseling. Not surprisingly, a study of patients with chordoma in the post-treatment phase demonstrated lower quality of life compared with the general population, and the most significant determinants were neurologic deficits (for example, bowel/bladder dysfunction and sensory deficits), pain medication use, corticosteroid use, and higher levels of depression⁷³. Another study assessing quality of life during treatment with proton beam therapy demonstrated no change in quality of life before and at completion of treatment, although the long-term impact has yet to be determined⁷⁴.

Future directions

The diagnosis and management of chordomas are evolving as surgical and adjuvant radiation techniques are continually being refined. The most promising treatments, however, lie in the ongoing molecular analysis of these tumors and the development of targeted therapy. Multiple trials have shown promising results with new experimental treatments. Hsu *et al.* demonstrated that silencing of the Brachyury gene can lead to the differentiation and senescence of chordoma cells²¹. Interestingly, Heery *et al.* demonstrated partial response in advanced chordoma patients who

received an immune-stimulating therapeutic cancer vaccine designed to elicit Brachyury-specific T-cell responses⁷⁵. Yang *et al.* reported growth inhibition in different chordoma cell lines after application of *SD-1029*, an inhibitor of Stat3 activation³⁴. The detection of *MTAP* deficiency in some chordomas by Sommer *et al.*³⁶ has introduced the possibility of targeting those *MTAP*-deficient chordomas with selective *de novo* purine synthesis inhibitors, a strategy that has been applied successfully to other types of *MTAP*-deficient tumors⁷⁶. Presneau *et al.* identified the activation of the *AKT/mTOR* pathway in the majority of chordomas, suggesting a potential therapeutic role for combined *AKT* and *mTOR* inhibitors, such as rapamycin or its analogues³³. Another target, *PDGFR*, has also been implicated in chordoma, and multiple studies on imatinib mesylate (alone or when combined with sirolimus) have shown antitumor activity in patients with chordoma^{77–80}. A phase II trial by the French Sarcoma Group studying sorafenib in locally advanced and metastatic chordoma has also shown promising results⁸¹. Similarly, Shalaby *et al.* reported *EGFR* as a potential therapeutic target as aberrances in

its signaling have been implicated in chordoma pathogenesis, arguing for a potential role of *EGFR* inhibitors in the management of some chordomas³⁵.

These findings represent a collective effort to expand our understanding of chordomas and to identify molecular targets that will allow the creation of more efficient and potentially personalized treatments. They also highlight the importance of an interdisciplinary collaboration between surgeons and scientists in an effort to continually improve our management of this complex disease.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- McMaster ML, Goldstein AM, Bromley CM, *et al.*: **Chordoma: incidence and survival patterns in the United States, 1973–1995.** *Cancer Causes Control.* 2001; 12(1): 1–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Llauger J, Palmer J, Amores S, *et al.*: **Primary tumors of the sacrum: diagnostic imaging.** *AJR Am J Roentgenol.* 2000; 174(2): 417–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mukherjee D, Chaichana KL, Gokaslan ZL, *et al.*: **Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.** *J Neurosurg Spine.* 2011; 14(2): 143–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
- Raffel C, Wright DC, Gutin PH, *et al.*: **Cranial chordomas: clinical presentation and results of operative and radiation therapy in twenty-six patients.** *Neurosurgery.* 1985; 17(5): 703–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fourney DR, Gokaslan ZL: **Current management of sacral chordoma.** *Neurosurg Focus.* 2003; 15(2): E9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bergh P, Kindblom LG, Gunterberg B, *et al.*: **Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.** *Cancer.* 2000; 88(9): 2122–34.
[PubMed Abstract](#)
- Eriksson B, Gunterberg B, Kindblom LG: **Chordoma. A clinicopathologic and prognostic study of a Swedish national series.** *Acta Orthop Scand.* 1981; 52(1): 49–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
- UTNE JR, PUGH DG: **The roentgenologic aspects of chordoma.** *Am J Roentgenol Radium Ther Nucl Med.* 1955; 74(4): 593–608.
[PubMed Abstract](#)
- Krol G, Sundaresan N, Deck M: **Computed tomography of axial chordomas.** *J Comput Assist Tomogr.* 1983; 7(2): 286–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Meyer JE, Oot RF, Lindfors KK: **CT appearance of clival chordomas.** *J Comput Assist Tomogr.* 1986; 10(1): 34–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Doucet V, Peretti-Viton P, Figarella-Branger D, *et al.*: **MRI of intracranial chordomas. Extent of tumour and contrast enhancement: criteria for differential diagnosis.** *Neuroradiology.* 1997; 39(8): 571–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rossleigh MA, Smith J, Yeh SD: **Scintigraphic features of primary sacral tumors.** *J Nucl Med.* 1986; 27(5): 627–30.
[PubMed Abstract](#)
- Williams BJ, Raper DM, Godbout E, *et al.*: **Diagnosis and treatment of chordoma.** *J Natl Compr Canc Netw.* 2013; 11(6): 726–31.
[PubMed Abstract](#)
- Müller H: **Über das Vorkommen von Resten der Chorda Dorsalis bei Menschen nach der Geburt und über die Verhältnisse zu den Gallertgeschwülsten am Clivus.** *Zeitung für Rationelle Medizin.* 1858; 2: 202–229.
- Adson AW, Kernohan JW, Woltman HW: **Cranial and cervical chordomas - A clinical and histologic study.** *Archives of Neurology and Psychiatry.* 1935; 33(2): 247–261.
[Publisher Full Text](#)
- Holland PW, Koschorz B, Holland LZ, *et al.*: **Conservation of Brachyury (T) genes in amphioxus and vertebrates: developmental and evolutionary implications.** *Development.* 1995; 121(12): 4283–91.
[PubMed Abstract](#)
- Yang XR, Ng D, Alcorta DA, *et al.*: **T (brachyury) gene duplication confers major susceptibility to familial chordoma.** *Nat Genet.* 2009; 41(11): 1176–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nibu Y, José-Edwards DS, Di Gregorio A: **From notochord formation to hereditary chordoma: the many roles of Brachyury.** *Biomed Res Int.* 2013; 2013: 826435.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Presneau N, Shalaby A, Ye H, *et al.*: **Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study.** *J Pathol.* 2011; 223(3): 327–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pillay N, Plagnol V, Tarpey PS, *et al.*: **A common single-nucleotide variant in T is strongly associated with chordoma.** *Nat Genet.* 2012; 44(11): 1185–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hsu W, Mohyeldin A, Shah SR, *et al.*: **Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.** *J Neurosurg.* 2011; 115(4): 760–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Miettinen M, Wang Z, Lasota J, *et al.*: **Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.** *Am J Surg Pathol.* 2015; 39(10): 1305–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Palena C, Roselli M, Litzinger MT, *et al.*: **Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.** *J Natl Cancer Inst.* 2014; 106(5): pii: dj0054.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Du R, Wu S, Lv X, *et al.*: **Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.** *J Exp Clin Cancer Res.* 2014; 33(1): 105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Yoshihama R, Yamaguchi K, Imajyo I, *et al.*: **Expression levels of SOX2, KLF4 and brachyury transcription factors are associated with metastasis and poor**

- prognosis in oral squamous cell carcinoma. *Oncol Lett.* 2016; **11**(2): 1435–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
26. **F** Jo VY, Hornick JL, Qian X: **Utility of brachyury in distinction of chordoma from cytomorphologic mimics in fine-needle aspiration and core needle biopsy.** *Diagn Cytopathol.* 2014; **42**(8): 647–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 27. Song W, Gobe GC: **Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers.** *Curr Cancer Drug Targets.* 2016; **16**(7): 586–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Tirabosco R, Mangham DC, Rosenberg AE, *et al.*: **Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue.** *Am J Surg Pathol.* 2008; **32**(4): 572–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Oakley GJ, Fuhrer K, Seethala RR: **Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis.** *Mod Pathol.* 2008; **21**(12): 1461–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. **F** Schwab JH, Boland PJ, Agaram NP, *et al.*: **Chordoma and chondrosarcoma gene profile: implications for immunotherapy.** *Cancer Immunol Immunother.* 2009; **58**(3): 339–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 31. Vujovic S, Henderson S, Presneau N, *et al.*: **Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.** *J Pathol.* 2006; **209**(2): 157–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. **F** Zhang L, Guo S, Schwab JH, *et al.*: **Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.** *PLoS One.* 2013; **8**(9): e75851.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 33. Presneau N, Shalaby A, Idowu B, *et al.*: **Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.** *Br J Cancer.* 2009; **100**(9): 1406–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. **F** Yang C, Schwab JH, Schoenfeld AJ, *et al.*: **A novel target for treatment of chordoma: signal transducers and activators of transcription 3.** *Mol Cancer Ther.* 2009; **8**(9): 2597–605.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 35. Shalaby A, Presneau N, Ye H, *et al.*: **The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.** *J Pathol.* 2011; **223**(3): 336–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Sommer J, Itani DM, Homlar KC, *et al.*: **Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.** *J Pathol.* 2010; **220**(5): 608–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Yang C, Hornicek FJ, Wood KB, *et al.*: **Characterization and analysis of human chordoma cell lines.** *Spine (Phila Pa 1976).* 2010; **35**(13): 1257–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Rinner B, Froehlich EV, Buerger K, *et al.*: **Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.** *Int J Oncol.* 2012; **40**(2): 443–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Diaz RJ, Guduk M, Romagnuolo R, *et al.*: **High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.** *Neoplasia.* 2012; **14**(9): 788–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. **F** Kitamura Y, Sasaki H, Kimura T, *et al.*: **Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.** *J Neuropathol Exp Neurol.* 2013; **72**(9): 816–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 41. **F** Scheil-Bertram S, Kappler R, von Baer A, *et al.*: **Molecular profiling of chordoma.** *Int J Oncol.* 2014; **44**(4): 1041–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 42. Duan Z, Choy E, Nielsen GP, *et al.*: **Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression.** *J Orthop Res.* 2010; **28**(6): 746–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. **F** Zhang Y, Schiff D, Park D, *et al.*: **MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.** *PLoS One.* 2014; **9**(3): e91546.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 44. **F** Osaka E, Yang X, Shen JK, *et al.*: **MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug.** *J Orthop Res.* 2014; **32**(8): 1075–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. **F** Scheipl S, Lohberger B, Rinner B, *et al.*: **Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis.** *J Orthop Res.* 2013; **31**(12): 1999–2005.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 46. Pallini R, Maira G, Pierconti F, *et al.*: **Chordoma of the skull base: predictors of tumor recurrence.** *J Neurosurg.* 2003; **98**(4): 812–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. York JE, Kaccaraj A, Abi-Said D, *et al.*: **Sacral chordoma: 40-year experience at a major cancer center.** *Neurosurgery.* 1999; **44**(1): 74–9; discussion 79–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Terahara A, Niemierko A, Goitein M, *et al.*: **Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma.** *Int J Radiat Oncol Biol Phys.* 1999; **45**(2): 351–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Catton C, O'Sullivan B, Bell R, *et al.*: **Chordoma: long-term follow-up after radical photon irradiation.** *Radiother Oncol.* 1996; **41**(1): 67–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Hsieh PC, Gallia GL, Sciubba DM, *et al.*: **En bloc excisions of chordomas in the cervical spine: review of five consecutive cases with more than 4-year follow-up.** *Spine (Phila Pa 1976).* 2011; **36**(24): E1581–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Tzortzidis F, Elahi F, Wright D, *et al.*: **Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas.** *Neurosurgery.* 2006; **59**(2): 230–7; discussion 230–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Yonemoto T, Tatzaki S, Takenouchi T, *et al.*: **The surgical management of sacrococcygeal chordoma.** *Cancer.* 1999; **85**(4): 878–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. **F** Jones PS, Aghi MK, Muzikansky A, *et al.*: **Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database.** *J Clin Neurosci.* 2014; **21**(9): 1490–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 54. Fraser JF, Nyquist GG, Moore N, *et al.*: **Endoscopic endonasal transclival resection of chordomas: operative technique, clinical outcome, and review of the literature.** *J Neurosurg.* 2010; **112**(5): 1061–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Saito K, Toda M, Tomita T, *et al.*: **Surgical results of an endoscopic endonasal approach for clival chordomas.** *Acta Neurochir (Wien).* 2012; **154**(5): 879–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Stippler M, Gardner PA, Snyderman CH, *et al.*: **Endoscopic endonasal approach for clival chordomas.** *Neurosurgery.* 2009; **64**(2): 268–77; discussion 277–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. **F** Chibbaro S, Cornelius JF, Froelich S, *et al.*: **Endoscopic endonasal approach in the management of skull base chordomas—clinical experience on a large series, technique, outcome, and pitfalls.** *Neurosurg Rev.* 2014; **37**(2): 217–24; discussion 224–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 58. Angelini A, Ruggieri P: **A new surgical technique (modified Osaka technique) of sacral resection by posterior-only approach: description and preliminary results.** *Spine (Phila Pa 1976).* 2013; **38**(3): E185–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. **F** Osaka S, Osaka E, Kojima T, *et al.*: **Long-term outcome following surgical treatment of sacral chordoma.** *J Surg Oncol.* 2014; **109**(3): 184–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 60. **F** Bederman SS, Shah KN, Hassan JM, *et al.*: **Surgical techniques for spinopelvic reconstruction following total sacrectomy: a systematic review.** *Eur Spine J.* 2014; **23**(2): 305–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 61. Tomita K, Kawahara N, Baba H, *et al.*: **Total en bloc spondylectomy. A new surgical technique for primary malignant vertebral tumors.** *Spine (Phila Pa 1976).* 1997; **22**(3): 324–33.
[PubMed Abstract](#)
 62. Guppy KH, Chakrabarti I, Isaacs RS, *et al.*: **En bloc resection of a multilevel high-cervical chordoma involving C-2: new operative modalities: technical note.** *J Neurosurg Spine.* 2013; **19**(2): 232–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Catton C, O'Sullivan B, Bell R, *et al.*: **Chordoma: long-term follow-up after radical photon irradiation.** *Radiother Oncol.* 1996; **41**(1): 67–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 64. **F** Weber DC, Malyapa R, Albertini F, *et al.*: **Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy.** *Radiother Oncol.* 2016; **120**(1): 169–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 65. **F** Matloob SA, Nasir HA, Choi D: **Proton beam therapy in the management of skull base chordomas: systematic review of indications, outcomes, and implications for neurosurgeons.** *Br J Neurosurg.* 2016; **30**(4): 382–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 66. **F** Rotondo RL, Folkert W, Liebsch NJ, *et al.*: **High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors.** *J Neurosurg Spine.* 2015; **23**(6): 788–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 67. Schulz-Ertner D, Karger CP, Feuerhake A, *et al.*: **Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas.** *Int J Radiat Oncol Biol Phys.* 2007; **68**(2): 449–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Imai R, Kamada T, Tsuji H, *et al.*: **Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials.** *Int J Radiat Oncol*

- Biol Phys.* 2010; **77**(5): 1470–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. **F** Mima M, Demizu Y, Jin D, *et al.*: **Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma.** *Br J Radiol.* 2014; **87**(1033): 20130512.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 70. Durante M, Loeffler JS: **Charged particles in radiation oncology.** *Nat Rev Clin Oncol.* 2010; **7**(1): 37–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Walcott BP, Nahed BV, Mohyeldin A, *et al.*: **Chordoma: current concepts, management, and future directions.** *Lancet Oncol.* 2012; **13**(2): e69–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Uhl M, Edler L, Jensen AD, *et al.*: **Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol.** *Radiat Oncol.* 2014; **9**: 100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. **F** Diaz RJ, Maggacis N, Zhang S, *et al.*: **Determinants of quality of life in patients with skull base chordoma.** *J Neurosurg.* 2014; **120**(2): 528–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 74. **F** Srivastava A, Vischioni B, Fiore MR, *et al.*: **Quality of life in patients with chordomas/chondrosarcomas during treatment with proton beam therapy.** *J Radiat Res.* 2013; **54**(Suppl 1): i43–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 75. Heery CS, Marte H, Madan J, *et al.*: **NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.** *J Clin Oncol.* 2014; **32**(15).
[Reference Source](#)
 76. Lubin M, Lubin A: **Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.** *PLoS One.* 2009; **4**(5): e5735.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Casali PG, Messina A, Stacchiotti S, *et al.*: **Imatinib mesylate in chordoma.** *Cancer.* 2004; **101**(9): 2086–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Stacchiotti S, Longhi A, Ferraresi V, *et al.*: **Phase II study of imatinib in advanced chordoma.** *J Clin Oncol.* 2012; **30**(9): 914–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Stacchiotti S, Marrari A, Tamborini E, *et al.*: **Response to imatinib plus sirolimus in advanced chordoma.** *Ann Oncol.* 2009; **20**(11): 1886–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. **F** Hindi N, Casali PG, Morosi C, *et al.*: **Imatinib in advanced chordoma: A retrospective case series analysis.** *Eur J Cancer.* 2015; **51**(17): 2609–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 81. **F** Bompas E, Le Cesne A, Tresch-Bruneel E, *et al.*: **Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).** *Ann Oncol.* 2015; **26**(10): 2168–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Maurice Matter**

Department of Visceral Surgery, University Hospital of Lausanne (CHUV), Lausanne, Switzerland

Competing Interests: No competing interests were disclosed.

2. **Omer Faruk Bayrak**

Department of Medical Genetics, Yeditepe University Medical School and Yeditepe University Hospital, Istanbul, Turkey

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research